Latest News

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

ALAR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

DVLT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Datavault AI Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately

Azerbaïdjan : TotalEnergies annonce la Décision Finale d’Investissement du développement Full Field d’Absheron

Azerbaijan: TotalEnergies Announces Final Investment Decision for Absheron Full Field Development

YYForce 发布 2026 年上半年财务业绩，营收同比增长 26.8% 至 3,270 万美元

Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva

Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP)

Mirum Pharmaceuticals et Incyte annoncent l’autorisation par la FDA américaine d’Atebrioz™ (zilurgisertib) pour les patients adultes et pédiatriques atteints de fibrodysplasie ossifiante progressive